FREE TRIAL
LOGIN
LOGIN

THERACRYF PLC

TRADE AIM SHARES
SEARCH COMPANIES
THERACRYF PLC ORD 0.25P TCF.L · LSE
Live
GBP 0.00 ▼ 0.00 (3.68%)
Mkt Cap £3.93M
Volume 2,052,271
52W 0.16 – 0.30
🔔 Sign in to receive sentiment alerts for THERACRYF PLC.
YOUR ALERTS

Market Sentiment

Sentiment Grade
A
↑ Improving (+3.4 pts vs 7-day avg)
THERACRYF PLC
Positive Sentiment
7.0/10
Sentiment Index
Very NegativeNeutralVery Positive
78%
Avg Confidence
25 / 1
Positive / Negative articles
📰 Based on 45 articles from 23 sources TradingView ×10 TipRanks ×5 Proactive Investors ×3 London South East ×3 Yahoo Finance UK ×3
📊 Low volatility — MEVI 14.9/100
🕐 Updated 4 hours ago
Today's context

Daily AI-generated context for this company — recent events, market backdrop, and supporting developments. Available to Pro Investor members.

📊
Full Analysis Available to Paid Members
Paid members get full access to detailed sentiment charts, article-level analysis, social media sentiment, confidence breakdowns, and historical trends and sentiment outlook on all companies on the site.
Sign in Register

Latest RNS & Market News

  • THERACRYF PLC – Successful Gmp Manufacture Advances Ox 1 To Clinic
    RNS Number : 0094B Theracryf PLC 20 April 2026     20 April 2026 TheraCryf plc (“TheraCryf”, the “Company” or the “Group”)   Lead Asset Ox-1 Advances Towards Clinic With Successful GMP Manufacture For Human Use Over 2kg of clinical-grade material produced to support Phase 1 trials TheraCryf plc (AIM: TCF), the biotech company developing…
  • THERACRYF PLC – New Manufacturing Process Patent For Ox 1
    RNS Number : 6260A Theracryf PLC 16 April 2026     16 April 2026 TheraCryf plc (“TheraCryf”, the “Company” or the “Group”)   New Manufacturing Process Patent Extends Exclusivity for Lead Asset Ox-1 Additional patent submission provides potential 20-year protection Strengthens long-term commercial value and partnering potential   TheraCryf plc (AIM: TCF), the biotech company…
LOGIN

Search For A Company

RISK WARNING